Toshihito Seki

Learn More
Cancer cells often gain advantage by reducing the tumor-suppressive activity of transforming growth factor-B (TGF-B) together with stimulation of its oncogenic activity as in Ras-transformed cells; however, molecular mechanisms remain largely unknown. TGF-B activates both its type I receptor (TBRI) and c-Jun NH 2-terminal kinase (JNK), which phosphorylate(More)
Rapid administration of large doses of ammonia leads to death of animals, which is largely prevented by pretreatment with N-methyl-D-aspartate (NMDA) receptor antagonists. The present study focuses on a subunit(s) of NMDA receptor involved in ammonia-induced death by use of NMDA receptor GluRepsilon subunit-deficient (GluRepsilon(-/-)) mice and the(More)
BACKGROUND We conducted a multicenter randomized clinical trial to determine the optimal treatment strategy against chronic hepatitis C virus (HCV) with genotype 1b and a high viral load (G1b/high). METHODS The study subjects included 153 patients with G1b/high. Patients were initially treated with PEG-IFNα-2a alone and then randomly assigned to receive(More)
Sorafenib is a multikinase inhibitor currently approved in Japan for the treatment of unresectable hepatocel-lular carcinoma. Interstitial pneumonia induced by sorafenib may have a fatal outcome, and therefore, has recently been the focus of many studies. The current report presents an autopsy case of diffuse alveolar damage (DAD) that occurred in a(More)
—Locoregional therapy (LT) is currently an advanced treatment for hepatocellular carcinoma (HCC) of liver in great demand. For evaluating the treated margin after locoregional therapy, doctors and radiologists trend to use some manual 3D image fusion application as a standard method to assess the results of locoregional therapy currently. However, liver is(More)
The assessment of the treated margin with locoregional therapy (LT), for hepatocellular carcinoma (HCC), is the common method for predicting HCC recurrence in most hospital. However, tumors sometimes cannot be removed clearly with LT in limited conditions. The therapeutic efficiency of HCC is often evaluated by comparing 2D fusion images of computed(More)
BACKGROUND SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We conducted a multicenter phase II trial in patients with HCC to evaluate the efficacy and safety of SM-11355, using a Zinostatin stimalamer suspension in iodized oil as a(More)
PURPOSE Assessing the treated region with locoregional therapy (LT) provides valuable information for predicting hepatocellular carcinoma (HCC) recurrence. The commonly used of assessment method is inefficient because it only compares two-dimensional CT images manually. In our previous work, we automatically aligned the two CT volumes to evaluate the(More)
Locoregional therapy (LT) is a popular method to cure hepatocellular carcinoma (HCC) of liver in the last few years. Evaluating the treated margin is a critical factor for predicting local recurrence after locoregional treatment is done. In this paper, we proposed a non-rigid registration method with constraint of anatomic landmarks for assessing treated(More)
  • 1